KIT and gastrointestinal stromal tumor: The characterization of recurrent mutations of cKIT in gastrointestinal stromal tumors (GIST) and TSC1/2 in malignant peripheral epithelioid cell tumors (PEComa) formed the basis for the respective repurposing of imatinib and sirolimus.